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and an adequate left ventricular function. A coronary spasm
secondary to capecitabin was suspected. The last dose of the
drug was given the morning of the coronary angiogram. The
patient presented a new chest pain episode a few hours after the
coronary angiogram. Betablockers were stopped and calcium-
blockers were introduced. Since then, the patient has not
presented any chest pain.
Cardiotoxicity is a recognized side effect of 5-fluorouracil
(5-FU), a related fiuorinated pyrimidine antagonist, and can
manifests as angina pectons, myocardial infarction, cardio-
genic shock, arrythmias and death [I]. Clinical evidence of
5-FU cardiotoxicity is generally considered to occur in about
2% of treated patients, probably more often in those with
known coronary disease and previous radiotherapy. Patients
have been reported to develop typical clinical and electro-
graphic manifestations within a few hours of initiating the
infusion to up to 18 hours after its completion. Symptoms and
ECG signs are known to subside at drug cessation, while
continuation of the drug has been associated with myocardial
infarction, pulmonary oedema and even death. Recurrence of
typical chest pain was observed with 5-FU rechallenge. Coro-
nary spasm is postulated to account for this cardiotoxicity [1,2]
though other mechanisms have been proposed [2].
Capecitabine is a fluoropyrimidine which after oral admin-
istration is metabolized into 5-FU by thymidine phosphorylase.
Since the metabolizing enzyme appears to be preferentially
expressed by tumor cells, capecitabine is considered to exert a
selective antitumoral action.
A recent randomized phase II study performed in 109
colorectal cancer patients reported 5 cases (4.5%) of probable
cardiac toxicity, including 4 patients with chest pain [3]. The
pain began four to eight days after initiation of treatment and
resolved with interruption of therapy. In two cases, rechallenge
with the drug was associated with pain relapse. ECG changes
were not reported in the article and no coronary angiogram
was performed. In the same article [3] preliminary data from
2 pooled randomized phase III studies performed in 596 patients
are mentioned (Van Cutsem E et al., manuscript in preparation):
2% cardiac events were observed in the capecitabin arm versus
1.3% in the 5-FU-leucovorin arm.
To our knowledge, no coronary spasm documented by
coronary angiogram and secondary to capecitabin has yet
been reported. We believe that our clinical observation should
remind physicians about the potential coronary toxicity of
capecitabine. Clinical and ECG manifestations of angina
should prompt drug discontinuation.
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Bone scan had no role in the staging
of 765 consecutive operable T1_2N0_i
breast cancer patients without
skeletal symptoms
Bone scanning (BS) is considered a sensitive test for the detec-
tion of metastatic breast cancer [1-3], but not all abnormal
findings on bone scan are diagnostic of skeletal metastasis. For
this reason, the role of BS in the staging of breast cancer has
been widely questioned in recent years [4—7]. Recent studies
have found a relatively low rate (less than or equal to 5%) of
abnormal scans in patients with stage I and II breast cancers,
and only half of those with positive scans subsequently had
documented bony metastasis [2]. Despite these data bone scan
continues to be prescribed during staging, and there was never
an intention to question the role of 'staging' bone scan imme-
diately after diagnosis and operation. The aim of this report
was to ascertain the relevance of bone scan (BS) in detecting
asymptomatic bone metastases in the preoperative staging of
disease in a group of patients studied by the same team of
physicians in a very short recruitment time. No previous study
reported our number of patients studied by the same team in
so short a recruitment time.
A retrospective review of 765 consecutive patients with
operable breast cancer staged according to the TNM staging
system asT|_2 , No_, and all referred to the European Institute
of Oncology (EIO) between April 1997 and January 2000, was
performed. No selection criteria have been used in our cohort.
Patients had a histologically proven breast cancer and had
definitive breast surgery and staging preoperative bone scan at
the EIO. All bone scans were performed and evaluated by the
same team of physicians at the Division of Nuclear Medicine.
Whole body scintigraphy was obtained three hours after in-
jection of 740 MBq of Technetium 99m-labeled methylene
diphosphonate in anterior and posterior projections by use of
a large-field gamma camera (GE MAXXUS) equipped with a
HR low energy collimator. Stage of disease was defined by
standard pathological examination techniques.
All patients were asymptomatic at the time of BS. Patient
characteristics are displayed in Table I. Increased uptake of
uncertain dignity was observed in 40 (5%) patients and
attributed, in differential diagnosis, to degenerative bone ab-
normalities or compression fractures of vertebrae. Detected
'hot spots' were investigated with the same type of radiologic
examination. An algorithm that provided X-ray and CT scan
Table I Major patient characteristics
Total
T,N0
T,N,
T2N0
T2N,
ER/PgR positive"
Grade 1
Grade 2
Grade 3
Grade nd
" ER and/or PgR :
Number of patients
765
261
237
109
158
652
126
354
274
II
> 10% of the cells or 10 fmoles.
True positive (%)
4(0.5)
-
1 (0 4)
-
3(2)
3(0 4)
3(0 8)
1(0 3)
-
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or MRI was used according to recommendations by the
radiologist. Only four patients had evidence of skeletal involve-
ment on imaging (X-ray, CTscan, MRI). In this subgroup of
patients we modified treatment strategy, but maintained indi-
cation for surgical breast conservation in patients with T|
lesions. No true positive was found among patients with node-
negative or grade 1 tumors. Thus, BS detected tumor bone
spread in 4 out of the 765 patients studied (0.5%), with a
positive predictive value of 10%.
Baseline bone scans had a cost of 240 Euro each (183,600
Euro total). Bone scans that were interpreted as positive or
suspicious for metastatic disease on initial presentation resulted
in 42 confirmatory studies, including 16 plain films, 18 computed
tomography (CT) scans, 8 magnetic resonance imaging (MRI)
scans. These additional tests cost another 9600 Euro.
Bone scan in the initial staging of breast cancer is not
mandatory. According to START (State of the Art Oncology
in Europe), accurate history and general examination, a full
blood count, liver function tests and a chest radiograph are
standard procedures on a general consensus basis in the pre-
operative evaluation of all patients with newly detected breast
cancer. Bone scan may also be requested by the patient, who
needs to be reassured about lack of evidence for tumor
dissemination. Most research protocols dealing with adjuvant
or neoadjuvant therapy for breast cancer require a baseline
bone scan, leading to the consideration of bone scan as a
routine examination for staging prior or, in asymptomatic
patients, immediately after breast cancer surgery.
A relevant staging is crucial for choosing a proper treatment.
In our study the cost-benefit balance of bone scintigraphy in the
initial staging of operable (T|_2, No_|) breast cancer excluded
any relevant role of this technique for the early detection of
metastatic bone metastases
Medical efforts and financial expenditures devoted to initial
breast cancer staging represents a heavy burden on health care
resources. We conclude that staging of asymptomatic Ti_2N0
breast cancer should not include bone scan as a routine
examination.
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